CORCEPT THERAPEUTICS INC Increase (Decrease) in Accrued Taxes Payable
CORCEPT THERAPEUTICS INC (CORT) reported Increase (Decrease) in Accrued Taxes Payable of $1.09 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedTaxesPayable · last filed 2026-02-24
- CORCEPT THERAPEUTICS INC increase (decrease) in accrued taxes payable for the quarter ending 2025-03-31 was $169.00K, a 69.93% decline year-over-year.
- CORCEPT THERAPEUTICS INC increase (decrease) in accrued taxes payable for the quarter ending 2024-03-31 was $562.00K, a 86.09% increase year-over-year.
- CORCEPT THERAPEUTICS INC increase (decrease) in accrued taxes payable for the quarter ending 2023-03-31 was $302.00K, a 85.67% decline year-over-year.
- CORCEPT THERAPEUTICS INC increase (decrease) in accrued taxes payable for the quarter ending 2022-03-31 was $2.11M, a 252.93% increase year-over-year.
- CORCEPT THERAPEUTICS INC increase (decrease) in accrued taxes payable for fiscal 2025 was $1.09M, a 71.09% decline from fiscal 2024.
- CORCEPT THERAPEUTICS INC increase (decrease) in accrued taxes payable for fiscal 2024 was $3.78M, a 212.15% increase from fiscal 2023.
- CORCEPT THERAPEUTICS INC increase (decrease) in accrued taxes payable for fiscal 2023 was $1.21M, a 86.07% decline from fiscal 2022.
- CORCEPT THERAPEUTICS INC increase (decrease) in accrued taxes payable for fiscal 2022 was $8.69M, a 78881.82% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Taxes Payable 3 month | Increase (Decrease) in Accrued Taxes Payable 12 month |
|---|---|---|
| 2025-12-31 | $1.09M 10-K · filed 2026-02-24 | |
| 2025-03-31 | $169.00K 10-Q · filed 2025-05-05 | |
| 2024-12-31 | $3.78M 10-K · filed 2026-02-24 | |
| 2024-03-31 | $562.00K 10-Q · filed 2025-05-05 | |
| 2023-12-31 | $1.21M 10-K · filed 2026-02-24 | |
| 2023-03-31 | $302.00K 10-Q · filed 2024-05-01 | |
| 2022-12-31 | $8.69M 10-K · filed 2025-02-26 | |
| 2022-03-31 | $2.11M 10-Q · filed 2023-05-03 | |
| 2021-12-31 | $11.00K 10-K · filed 2024-02-15 | |
| 2021-03-31 | $597.00K 10-Q · filed 2022-05-05 | |
| 2020-12-31 | $12.00K 10-K · filed 2023-02-28 | |
| 2020-03-31 | $0.00 10-Q · filed 2021-05-06 | |
| 2019-12-31 | $147.00K 10-K · filed 2022-02-15 | |
| 2018-12-31 | $239.00K 10-K · filed 2021-02-23 | |
| 2017-12-31 | $0.00 10-K · filed 2020-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |